Online inquiry

IVTScrip™ mRNA-Anti-EGFR, 1-26/3-67(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (CAT#: GTTS-WQ161MR)

This product GTTS-WQ161MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Solid tumors research.

Specifications
Product type	mRNA
Modified bases	N1-Methylpseudo-UTP
5' Cap	Cap 0
Species	Humanized
RefSeq	NM_001346897.2
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	1956
UniProt ID	Q504U8

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, 1-26/3-67(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ161MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ2174MR	IVTScrip™ mRNA-Anti-IL15, ALT-803(Cap 1, Pseudo-UTP, 120 nt-poly(A))	mRNA	ALT-803
GTTS-WQ12786MR	IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 1, Pseudo-UTP, 120 nt-poly(A))	mRNA	OMP-59R5
GTTS-WQ10395MR	IVTScrip™ mRNA-Anti-TNFSF13B, LY2127399(Cap 0, 2-Thio-UTP, 120 nt-poly(A))	mRNA	LY2127399
GTTS-WQ6844MR	IVTScrip™ mRNA-Anti-IL3RA, DT-IL-3(Cap 1, 2-Thio-UTP, 120 nt-poly(A))	mRNA	DT-IL-3
GTTS-WQ1768MR	IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 0, Pseudo-UTP, 30 nt-poly(A))	mRNA	ADCT-301(unconjugated)
GTTS-WQ5750MR	IVTScrip™ mRNA-Anti-EGFR, CetuxiMab-GEX(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))	mRNA	CetuxiMab-GEX
GTTS-WQ7550MR	IVTScrip™ mRNA-Anti-GPC3, GC33(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))	mRNA	GC33
GTTS-WQ13233MR	IVTScrip™ mRNA-Anti-TNFRSF9, PF-05082566(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))	mRNA	PF-05082566

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST